<DOC>
	<DOCNO>NCT02596191</DOCNO>
	<brief_summary>This 2-year follow-up study cohort 60 CMT1A patient . The objective identify marker allow good understand phenotypic variability observe patient CMT1A , identify predictive marker disease 's progression provide validate measurement tool use outcome measure future clinical trial .</brief_summary>
	<brief_title>Tools Therapeutic Evaluation Charcot-Marie-Tooth Disease Type 1A : Outcome Measures Biomarkers</brief_title>
	<detailed_description />
	<mesh_term>Tooth Diseases</mesh_term>
	<mesh_term>Charcot-Marie-Tooth Disease</mesh_term>
	<mesh_term>Nerve Compression Syndromes</mesh_term>
	<mesh_term>Hereditary Sensory Motor Neuropathy</mesh_term>
	<criteria>Patients CMT 1A disease Diagnosis CMT 1A confirm genotyping ( duplication 17p11.2 region ) Patients suffer comorbidity origin peripheral neuropathy ( diabetes , hypothyroidism , renal insufficiency , drug ... ) muscle , articular , rheumatological disease With HIV cancer With significant progressive disease previous month With contraindication MRI With dislocation , fracture , recent surgery ( le 6 month inclusion ) alcohol psychoactive substance abuse Treated antiinflammatory drug past four week Pregnant breastfeed woman Homeless patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>